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Abstract
Mutations in the F-box only protein 7 gene (FBXO7) cause PARK15, an autosomal recessive neurodegenerative disease
presenting with severe levodopa-responsive parkinsonism and pyramidal disturbances. Understanding the PARK15
pathogenesis might thus provide clues on the mechanisms of maintenance of brain dopaminergic neurons, the same which
are lost in Parkinson’s disease. The protein(s) encoded by FBXO7 remain very poorly characterized. Here, we show that two
protein isoforms are expressed from the FBXO7 gene in normal human cells. The isoform 1 is more abundant, particularly in
primary skin fibroblasts. Both isoforms are undetectable in cell lines from the PARK15 patient of an Italian family; the isoform
1 is undetectable and the isoform 2 is severely decreased in the patients from a Dutch PARK15 family. In human cell lines
and mouse primary neurons, the endogenous or over-expressed, wild type FBXO7 isoform 1 displays mostly a diffuse
nuclear localization. An intact N-terminus is needed for the nuclear FBXO7 localization, as N-terminal modification by
PARK15-linked missense mutation, or N-terminus tag leads to cytoplasmic mislocalization. Furthermore, the N-terminus of
wild type FBXO7 (but not of mutant FBXO7) is able to confer nuclear localization to profilin (a cytoplasmic protein). Our data
also suggest that overexpressed mutant FBXO7 proteins (T22M, R378G and R498X) have decreased stability compared to
their wild type counterpart. In human brain, FBXO7 immunoreactivity was highest in the nuclei of neurons throughout the
cerebral cortex, intermediate in the globus pallidum and the substantia nigra, and lowest in the hippocampus and
cerebellum. In conclusion, the common cellular abnormality found in the PARK15 patients from the Dutch and Italian
families is the depletion of the FBXO7 isoform 1, which normally localizes in the cell nucleus. The activity of FBXO7 in the
nucleus appears therefore crucial for the maintenance of brain neurons and the pathogenesis of PARK15.
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Introduction
Parkinson’s disease (PD), the second most common neurode-
generative disorder after Alzheimer’s disease, is pathologically
characterized by the progressive loss of dopaminergic neurons in
the substantia nigra of the midbrain, and the formation of alpha-
synuclein-containing protein aggregates, termed Lewy bodies, in
surviving neurons [1]. In recent years, defective ubiquitin-
proteasome system, mitochondrial dysfunction, oxidative stress,
and autophagy impairment have all been suggested to play some
roles in the PD pathogenesis, but the primary molecular
mechanisms of this disease remain mostly unknown [2,3]. PD is
a sporadic, idiopathic disorder in most patients, but the
identification of genetic mutations causing rare Mendelian forms
of parkinsonism has provided novel clues for understanding of the
disease pathogenesis [3,4]. Some of these Mendelian parkinson-
ism, such as those caused by dominant mutations in the alpha-
synuclein (PARK1) or leucine-rich repeat kinase 2 (PARK8) gene, are
more similar to the common, idiopathic PD form [5]. In other
forms, such as those caused by recessive mutations in the parkin
(PARK2), PINK1 (PARK6), DJ-1 (PARK7), and ATP13A2
(PARK9), the phenotype is more often atypical due to younger-
onset, presence of additional clinical signs (dementia, pyramidal
signs), or absence of Lewy body-pathology [6,7,8]. However,
despite these atypical phenotypes, understanding the mechanisms
of the Mendelian parkinsonisms might provide important clues
into the pathways leading to the degeneration of the dopaminergic
neurons, which might also be involved in the common forms of
PD. For example, the ATP13A2 protein has been recently
identified as a potent modifier of the toxicity induced by alpha-
synuclein in animal models of PD [9].
Recently, we characterized mutations in the F-box only protein 7
(FBXO7) gene, encoding the F-box protein 7 (FBXO7), as the
cause of PARK15, an autosomal recessive neurodegenerative
disease presenting with juvenile, severe levodopa-responsive
parkinsonism and additional pyramidal signs [10]. A homozygous
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FBXO7 nonsense mutation (R498X) is present in an Italian family,
while compound heterozygous mutations (IVS7+1G/T and a
T22M mutation) are found in a Dutch family. Another
homozygous mutation (R378G) was previously identified by others
in an Iranian family [11].
FBXO7 is a member of the F-box-containing protein (FBP)
family, characterized by a ,40-amino acids domain (the F-box)
[12,13,14]. FBPs serve as molecular scaffolds in the formation of
protein complexes, and have been implicated in a range of
processes, such as cell cycle, genome stability, development,
synapse formation, and circadian rhythms (reviewed in [15]).
Through the interaction between the F-box and the Skp1 protein,
FBPs might become part of SCF (Skp1, Cullin1, F-box protein)
ubiquitin ligase complexes, and play roles in ubiquitin-mediated
proteasomal degradation [15]. However, FBPs might also be
involved in ubiquitin-mediated, non-proteasomal pathways, and
SCF-independent non-proteolytic functions [15].
Two FBXO7 transcript variants are annotated in Genbank
(accession number NM_012179.3 and NM_001033024.1), result-
ing from the usage of different open reading frame (ORF) start
codons on alternatively spliced 59-exons, and predicted to encode
two FBXO7 protein isoforms of 522 and 443 amino acids
(also referred to as isoform 1 and isoform 2). However, the
experimental confirmation of the existence of these two protein
isoforms has remained elusive. Nothing is known about the
expression of the FBXO7 protein(s) in the human brain.
The FBXO7 isoform 1 is longer than isoform 2 because of the
presence of an N-terminal ubiquitin-like (Ubl) domain (absent in
the isoform 2), which is thought to interact with ubiquitin receptor
proteins (Figure 1). The remaining domains are present in both
isoforms, including an FP (FBXO7/PI31) domain, the F-box
motif, and a C-terminal proline-rich region (PRR). The FP
domain mediates the interaction of FBXO7 with the proteasome
inhibitor protein PI31 [16]. The PRR appears crucial for the
binding of FBXO7 to its reported substrates.
Very little is known about the function and the sub-cellular
localization of these two FBXO7 proteins. FBXO7 has been
reported to interact with the hepatoma up-regulated protein
(HURP, a mitotic protein) [17], the inhibitor of apoptosis protein
1 (cIAP1) [18], and the proteasome inhibitor protein PI31 [16].
Last, FBXO7 was shown to possess SCF-independent transform-
ing activity by enhancing the interaction of cyclin-dependent-
kinase CDK6 with its targets [19]. Whether these or other still
unknown FBXO7 interacting-proteins are important for the
Figure 1. Schematic representation of the FBXO7 transcripts and protein isoforms. (A) The FBXO7 transcripts with location of the mutations
found in patients with PARK15. The location of the primers used in qPCR is indicated by arrows. (B) Domain organization of the two FBXO7 protein
isoforms. Ubl: ubiquitin-like domain; FP: FBXO7/ PI31 domain; F-box: F-box motif; PRR: proline rich domain.
doi:10.1371/journal.pone.0016983.g001
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neuronal function of FBXO7 and for the mechanisms of
neurodegeneration remains unknown. Here, we show the
existence of two FBXO7 protein isoforms in normal human cells;
we characterize their subcellular localization and their differential
depletion in cell lines from the patients with PARK15; last, we
characterize the expression of the FBXO7 proteins in the normal
human brain.
Results
Expression of the FBXO7 proteins in families with PARK15
To study the expression of the endogenous FBXO7 proteins, we
obtained Epstein-Barr virus (EBV)-transformed lymphoblastoid
cell lines from members of the Italian and Dutch PARK15
families, and from unrelated normal controls. Fibroblast lines were
also established from skin biopsies in one Dutch PARK15 patient
and one unrelated control. Unfortunately, fibroblasts from the
second Dutch PARK15 patient and from patients of the Italian
PARK15 family were not available.
In lymphoblastoid cells from normal controls (Figures 2 and 3),
and HEK 293T cells (Figure S1), our Western blot (WB) analysis
using an antibody against FBXO7 revealed two bands of the
expected molecular weight of the FBXO7 isoform 1 and isoform 2.
The knock down (KD) of FBXO7 gene in HEK 293T cells
confirmed the specificity of the antibody for the FBXO7 proteins
(Figure S1).
In the Dutch family, two siblings were affected by PARK15 and
they carried compound heterozygous FBXO7 mutations: the
splice-site mutation IVS7+1G/T, which removes the invariable
splice donor of intron 7 and is expected to disrupt the splicing of
both the FBXO7 transcript isoforms; and a substitution in exon 1A,
c.C65T, predicted to lead to the missense change p.T22M, but
only in the longer FBXO7 protein isoform 1 (Figure 2A). We
previously documented the expression of both FBXO7 alleles in
these patients, by verifying the presence of the heterozygous
c.C65T mutation in cDNA from blood cells [10]. We also showed
multiple aberrantly spliced transcripts resulting from the activation
of cryptic splice sites in exon 7, and encoding frame-shift proteins
followed by premature truncation [10]. These are usually unstable
and rapidly degraded by the cell.
In the Dutch PARK15 patients, the FBXO7 isoform 1 was
undetectable in WB, while the isoform 2 was detected in lower
amounts (Figure 2C). The unaffected mother (NIJ-001) who only
carried the T22M mutation, showed lower amount of the isoform
Figure 2. Expression of FBXO7 in the Dutch PARK15 family. (A) Family pedigree and FBXO7 genotypes. (B) qPCR analysis of FBXO7 mRNA
(both transcript isoforms) in members of the PARK15 family and unrelated, healthy controls (C1–C3). (C) Western blotting analysis. The two FBXO7
isoforms present in controls are altered in the mutation carriers. The isoform 1 is undetectable in the patients (NIJ-002 and NIJ-006) and decreased in
the mother (NIJ-001), who also carries the mutation affecting this isoform (T22M). The isoform 2 is decreased in the patients and normal in the mother
(see text for further details).
doi:10.1371/journal.pone.0016983.g002
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1, and normal amount of isoform 2. These results are compatible
with lack of FBXO7 protein expression from the allele containing
the IVS7+1G/T mutation, and with only isoform 2 being
expressed from the allele containing the T22M mutation. In other
words, the T22M mutation leads to selective depletion of the
isoform 1, the only isoform in which this mutation is incorporated.
To exclude effects of these mutations at mRNA level, or
presence of other, unknown mutations in linkage disequilibrium,
we performed quantitative PCR (qPCR) analysis of the total
FBXO7 transcripts, as well as the isoform 1-specific and the
isoform 2-specific transcripts separately. These experiments
showed that the FBXO7 mRNA levels in the Dutch patients were
similar to those in unrelated controls (Figure 2B and Figure S3),
suggesting that the main effect of these mutations is at the level of
protein stability.
The two affected siblings in the Italian PARK15 family carry an
FBXO7 homozygous nonsense mutation in exon 9, predicted to
affect both transcripts (c.C1492T, according to the longer FBXO7
transcript, protein effect p.R498X) (Figure 3A). qPCR analysis
showed similar FBXO7 mRNA levels among unrelated healthy
controls, R498X heterozygous and homozygous mutation carriers
(Figure 3B and Figure S3), indicating that this truncating mutation
escapes nonsense-mediated mRNA decay [20]. However, in WB
analysis, the R498X heterozygous carriers displayed reduced levels
of both the FBXO7 protein isoforms, while the FBXO7 proteins
were both undetectable in the homozygous PARK15 patient
(Figure 3C). Unfortunately, the second patient in this family died
before cell lines could be obtained. Thus, in the case of this
nonsense mutation, the main final effect is the depletion of both
FBXO7 protein isoforms, likely due to protein instability. Since
this mutation only removes the last 24 residues of FBXO7, the C-
terminus appears therefore very important for the stability of this
protein.
Subcellular localization of wild type and mutant FBXO7
To investigate the subcellular localization of FBXO7, we
transiently transfected HEK 293T cells with plasmids overex-
pressing the wild type (WT) or mutant FBXO7 isoform 1. Forty-
eight hours after transfection we analyzed the cells by immuno-
fluorescence and confocal microscopy. In mock transfected HEK
293T cells, a main nuclear and much weaker cytosolic staining was
observed (Figure 4A). FBXO7 stable knock-down in these cells
confirmed the specificity of the staining, which represents therefore
the endogenous FBXO7 protein (Figure S2). The overexpression
of the WT FBXO7 isoform 1 in HEK 293T cells resulted in a
mostly nuclear staining, a pattern shared by the R378G mutant
Figure 3. Expression of FBXO7 in the Italian PARK15 family. (A) Family pedigree and FBXO7 genotypes. (B) qPCR analysis of FBXO7 mRNA
(both transcript isoforms) in members of the PARK15 family and unrelated, healthy controls (C1–C3). (C) Western blotting analysis. The two FBXO7
isoforms present in controls are both undetectable in the PARK15 patient (BO-53), and markedly decreased in the heterozygous mutation carriers
(BO-51, BO-52, BO-55). The BO-54 subject is not a carrier of the mutation and shows normal FBXO7 expression.
doi:10.1371/journal.pone.0016983.g003
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(Figure 4B and Figure 4C). A much weaker signal was still diffusely
detected in the cytoplasm.
To confirm the localization of endogenous wild type and
mutant FBXO7, we performed immunofluorescence in fibroblasts
from one Dutch PARK15 patient, and one unrelated normal
control (Figure 5). A pattern of mainly nuclear fluorescence
(similar to that seen in HEK 293T cells in Figure 4A) was often
observed in the control fibroblasts, but never in the patient
fibroblasts (Figure 5). WB analysis confirmed the expression of two
FBXO7 isoforms in normal fibroblasts (Figure 5D); compared with
Figure 4. Localization of FBXO7 in HEK 293T cells. Cells were transfected with empty vector (mock, A), wild type FBXO7 (B), R378G mutant (C),
R498X mutant (D), T22M mutant (E) and N-terminus-tagged eGFP-FBXO7 (F). In panels A–E, the FBXO7 protein is visualized in red by using a mouse
primary anti-FBXO7 antibody and a Cy3-coupled secondary anti-mouse antibody. In panel F, the FBXO7 protein is directly visualized by the green
eGFP signal. The nucleus (Hoechst staining) is depicted in green, with the exception of panel F, where it is stained in blue (scale bars, 10 mm). (G)
Quantification of the nuclear localization of FBXO7. At least 200 HEK 293T cells expressing FBXO7 were counted. *** p,0.01 (chi-square test - T22M
versus wild type and other FBXO7 variants).
doi:10.1371/journal.pone.0016983.g004
Figure 5. Expression of endogenous FBXO7 in human fibroblasts. (A, B) For immunofluorescence, the FBXO7 protein is visualized in red by
using a mouse primary anti-FBXO7 antibody and a Cy3-coupled secondary anti-mouse antibody. The nucleus (Hoechst staining) is depicted in green.
(scale bars, 10 mm). (A) normal control; (B) Dutch PARK15 patient with T22M and IVS7+1G/T mutations. (C) quantification of percentages of cells
showing mainly nuclear localization of FBXO7. (D) Western blotting analysis of fibroblasts from a normal control and the Dutch PARK15 patient.
doi:10.1371/journal.pone.0016983.g005
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lymphoblasts, here the isoform 1 was much more abundant than
isoform 2. In the fibroblasts from the Dutch PARK15 patient, the
isoform 1 was undetectable by WB, while isoform 2 was detected,
in agreement with the results of WB in lymphoblastoid cells from
the same patient (Figure 2C). Taken together, the experiments in
the patients fibroblasts show that the loss of isoform 1 (WB) is
associated with the loss of immunoreactivity in the nucleus (seen in
immunofluorescence). The weak cytosolic immunoreactivity is
compatible with the residual expression of isoform 2 seen in this
patient in WB.
The FBXO7 R498X mutant displayed an abnormal pattern
consisting of diffuse nuclear and cytosolic localization when
overexpressed in HEK 293T cells (Figure 4D). Last, the T22M
mutant showed the most striking aberrant pattern of mostly
cytosolic localization (Figure 4E and Figure 4G). The T22M
mutation is close to the N-terminus where it might impair a
nuclear localization signal. To test this hypothesis, we overex-
pressed WT FBXO7 with an N-terminal tag (enhanced green
fluorescent protein, eGFP). As expected, the N-terminal tagging
totally blocked the nuclear localization of the protein (Figure 4F),
mimicking the pattern of the T22M mutant. Furthermore, the
first 40 amino acids of WT or T22M-mutant FBXO7 isoform 1
were cloned in front of the mCherry-labeled profilin, a well-
known cytosolic protein. As a result, the WT FBXO7 N-terminal
40 amino acid peptide, but not the T22M-mutant, was able to
change the localization of profilin from cytoplasm to nucleus
(Figure 6).
The localization pattern of WT- and mutant FBXO7 proteins
in human neuroblastoma SH-SY5Y cells and mouse primary
hippocampal neurons were similar to those described in HEK
293T cells (Figure 7A–I).
Stability of mutant FBXO7 in vitro
On the basis of the WB and qPCR observations on the cells
from the PARK15 patients, we hypothesized that the missense and
nonsense mutants (T22M and R498X) markedly decreased the
stability of FBXO7.
To test this hypothesis, the WT and mutant FBXO7 (T22M and
R498X) were transfected in HEK 293T cells. The R378G mutant
reported previously in an Iranian PARK15 family [11] was also
tested. The overexpression of all these FBXO7 mutants yielded
consistently and significantly decreased levels in WB compared
with their WT counterpart (Figure 8A–B). This is consistent with
our observations in the patients cells and suggest that the FBXO7
mutants are rapidly degraded. To explore the degradation
pathways of FBXO7, the lysosomal inhibitor NH4Cl or the
proteasome inhibitor MG-132 were added to the cells overex-
pressing WT and mutant FBXO7. Treatment with NH4Cl
strongly inhibited the degradation of FBXO7, increasing the
steady-state protein expression by three to four fold (Figure 8C–D),
which suggests that overexpressed FBXO7 is mainly degraded by
the lysosomal pathway. The treatment with MG-132 leads to
smaller increases in steady-state FBXO7 expression (Figure 8E–F),
indicating a minor role of the proteasome degradation pathway.
To control for the transfection efficiency, the WT and mutant
FBXO7 (T22M, R378G, and R498X) were transfected in HEK
293T cells together with the eGFP protein. Similar results were
obtained (Figure S4).
FBXO7 proteins expression in the human brain
To characterize the expression of the FBXO7 proteins in the
human brain, we studied the following brain regions by
immunohistochemistry: frontal, temporal, and occipital cerebral
Figure 6. The N-terminus of FBXO7 confers nuclear localization to profilin. In panel (A), Profilin, a well-known cytosolic protein, is visualized
by the red mCherry signal; the nucleus is depicted in green (Hoechst staining). Expressing the first 40 amino acids of WT-FBXO7 isoform 1 in front of
mCherry-labeled profilin changes the localization of profilin from the cytoplasm to the nucleus (B). The same FBXO7 N-terminal peptide carrying the
T22M-mutation found in PARK15 patients is totally devoid of this capacity (C). (scale bars, 10 mm).
doi:10.1371/journal.pone.0016983.g006
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cortex, hippocampus, globus pallidum, substantia nigra, and
cerebellar cortex. The immunoreactivity was highest in the nuclei
of neurons throughout the cerebral cortex, intermediate in
neurons in the globus pallidum and the substantia nigra, and
lowest in the hippocampus (Figure 9) and cerebellar cortex (not
shown).
Discussion
Recessive FBXO7 mutations are definitely established as the
cause of PARK15, a novel form of juvenile neurodegenerative
parkinsonism with additional pyramidal signs [10,11]. However,
very little is known about the biology of the FBXO7 proteins. Even
the existence of the two protein isoforms remained to be
confirmed, the subcellular localization was poorly characterized,
and the expression in the human brain unexplored. A localization
of overexpressed FBXO7 to the cytoplasm and nucleus has been
reported in previous studies which all used N-terminal tags to
visualize FBXO7 (mostly isoform 1), and did not control for tag-
related effects [16,18,19]. The N-terminal tagging was probably
responsible for the observed cytosolic localization of FBXO7 in
those studies. The localization of the over-expressed untagged
FBXO7 or of the endogenous FBXO7 was not previously
investigated. This uncertainty in the subcellular localization of
the FBXO7 protein also complicates the interpretation of the
biological plausibility of the reported interactions with other
proteins. On the other hand, it is crucial to assess whether the
FBXO7 disease-causing mutations affect protein stability, before
these mutants are used in functional studies and conclusions are
made about possible pathogenetic mechanisms.
A first important message of this study is that two FBXO7
protein isoforms are expressed in normal human cells. This
contention is supported by the fact that the two FBXO7
immunoreactive bands are both undetectable in HEK 293T cells
with stable FBXO7 gene KD, and in the cells from the patients
with PARK15 who carry a homozygous truncating mutation
predicted to affect both the FBXO7 transcripts. In keeping with
this model, only the FBXO7 isoform 1 is markedly depleted in the
Dutch patients, as one of the mutations present in those patients
(T22M) is indeed only affecting the isoform 1, leaving the isoform
2 unaffected. Thus, the Dutch patients are still able to express the
isoform 2 from this mutant allele, while the other allele (carrying
the IVS7+1G/T splice mutation) disrupts the expression of both
isoforms. Interestingly, the heterozygous mutation carriers of the
Italian family, who display lower levels of both FBXO7 isoforms,
remain healthy (Figure 3). On the contrary, the Dutch patients,
who still express low levels of only the isoform 2, are affected
(Figure 2). This strongly suggests that the depletion of the isoform
1 is the culprit for the pathogenesis of PARK15.
Furthermore, we show that the overexpressed, untagged FBXO7
isoform 1 and also the endogenous FBXO7 protein are mostly
localized to the cell nucleus in two human cell models (HEK 293T
and SH-SY5Y), as well as in mouse primary hippocampal neurons
and human skin fibroblasts. We also show that an intact N-terminus
is essential for proper nuclear localization of FBXO7 isoform 1.
Modifications in this region of FBXO7, including the missense
T22M mutation or N-terminal tagging by eGFP, lead to
mislocalization to the cytoplasm. These observations also support
the contention that previous reports of cytoplasmic localization of
FBXO7 are probably due to N-terminal tagging.
Figure 7. Localization of FBXO7 in SH-SY5Y cells and primary hippocampal neurons. Neuroblastoma SH-SY5Y cells (A–E) and mouse
primary hippocampal neurons (F–I) were transfected with empty vector (mock, A), wild type FBXO7 (B, F), R378G mutant (C, G), R498X mutant (D, H),
and T22M mutant (E, I) FBXO7. The FBXO7 protein is visualized in red by using a mouse primary anti-FBXO7 antibody and a Cy3-coupled secondary
anti-mouse antibody. The nucleus (Hoechst staining) is depicted in green. (scale bars, 20 mm).
doi:10.1371/journal.pone.0016983.g007
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Canonical nuclear localization signals are not present in the
N-terminus of FBXO7. However, nucleus localization signals
might also consist of one or more short sequences of positively
charged lysine or arginine residues, which are indeed present in
the N-terminus of FBXO7 (Figure S5) [21,22]. The effects of N-
terminal tagging would therefore be explained by the masking of
these signals. How the T22M mutation prevents the nuclear
localization of overexpressed FBXO7 is unclear, but the
mutation might affect the interaction with other proteins which
are crucial for the nuclear import of FBXO7. In support of this
contention, we showed that the first 40 amino acids of FBXO7
isoform 1 are crucial for nuclear localization, as they efficiently
direct profilin (a cytosolic protein) to the nucleus; however, the
T22M mutation suppresses this effect. The C-terminus of the
protein might also contain important motifs for nuclear import
or export, as the overexpressed R498X mutant also displays an
Figure 8. Overexpression of wild type and mutant FBXO7. Overexpression of wild type and mutant FBXO7 proteins in HEK 293T cells (A), and
effect of the treatment with the lysosomal inhibitor NH4Cl (C) and the proteasomal inhibitor MG-132 (E). Actin is used as loading control. The
quantification of the protein levels is shown in the right panels (B, D, and F) (Odyssey software).
doi:10.1371/journal.pone.0016983.g008
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abnormal pattern of equally diffuse, cytosolic and nuclear
localization.
Regarding the stability of the FBXO7 missense and truncated
proteins encoded by the mutations causing PARK15, our data
collectively suggest that the T22M, R378G and R498X mutants
are all significantly unstable compared with the WT protein, at
least in our overexpressing systems (Figure 8 and Figure S4). It is
possible that the overexpressed FBXO7 mutants were insoluble
and therefore not present in the cell lysate fraction. We therefore
detected FBXO7 in insoluble fractions, but the amount of FBXO7
mutants was still lower than that of the WT counterpart (data not
shown). Furthermore, formation of inclusions or membrane
association of overexpressed FBXO7 was not observed. Last, we
showed that the overexpressed WT and mutant FBXO7 are
mainly degraded via the lysosomal pathway, with also a minor role
of the proteasome pathway. Our data also suggest that the
overexpressed R378G mutant is less stable than the WT FBXO7.
The Iranian PARK15 patients might thus also suffer a severe
depletion of the endogenous protein. It will be of interest to test
this prediction in patients-derived cells, since we found that
R378G does not significantly alter the nuclear localization in
transfected cells. If sufficiently stable, this mutant protein could
provide important clues about the nuclear function of FBXO7 that
is lost in PARK15.
Last, we provide the initial characterization of the expression of
the FBXO7 proteins in the normal human brain by immunohis-
tochemistry. The nuclei of neurons throughout the cerebral cortex
showed the strongest FBXO7 immunoreactivity, followed by the
neurons in the subcortical diencephalic region, and the substantia
nigra, while the lowest immunoreactivity was detected in the
hippocampus and the cerebellar cortex (Figure 9 and data not
shown).
Limited data on the expression of the FBXO7 gene at mRNA
level were reported in one of the studies that originally
characterized this gene (named FBX therein) [14]. The FBXO7
mRNA appeared to be broadly expressed in human tissues, but
enriched in bone marrow, liver, kidney, testis, and thyroid gland.
Interestingly, a strong expression was also found in several regions
of the human brain, such as the corpus callosum, caudate nucleus,
substantia nigra, as well as in the spinal cord [14]. Furthermore,
microarray data on the regional expression of the FBXO7 gene in
the human brain, are available in the ALLEN Human Brain Atlas
website (http://www.brain-map.org, accessed on Dec. 1, 2010). In
this Atlas, FBXO7 expression levels are high in the cerebral cortex
(particularly the frontal and parietal regions), the striatum,
pallidum, thalamus, substantia nigra, red nucleus, and deep
cerebellar nuclei, while low expression levels are documented in
the hippocampus and the cerebellar cortex.
Figure 9. Expression of the FBXO7 protein in the normal human brain. Brain sections are stained using anti-FBXO7 antibody (Abnova):
frontal (A), temporal (B), and occipital (C) cortex; globus pallidum (D); substantia nigra (E); dentate gyrus of hippocampus (F). (scale bars, 100 mm).
doi:10.1371/journal.pone.0016983.g009
Nuclear Activity of FBXO7 Is Lost in PARK15
PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e16983
The FBXO7 mRNA and proteins seem therefore highly
expressed in the motor areas of the human brain, including both
the extrapyramidal and the pyramidal systems, which fits with the
clinical phenotype of parkinsonian-pyramidal disorder caused by
the loss of the FBXO7 function in PARK15. Intriguingly, the
widespread and abundant expression of the FBXO7 proteins in
the frontal cerebral cortex suggests that additional, cognitive and
behavioural disturbances of frontal type might be prominent in the
phenotype. Interestingly, severe behavioural disturbances were
noted in one of the Dutch PARK15 patients [10].
In conclusion, the common cellular abnormality found in the
PARK15 patients from the Dutch and Italian families is the
depletion of the FBXO7 isoform 1, which normally localizes
mostly in the cell nucleus. The activity of FBXO7 in the nucleus
appears therefore crucial for the maintenance of brain neurons
and the pathogenesis of PARK15.
Materials and Methods
Ethics Statement
The study was approved by the Medical Ethical Committee
(Medisch Ethische Toetsings Commissie, METC) of the Erasmus
MC Rotterdam, and all participating subjects provided their
informed consent.
Subjects
The Dutch and Italian families with FBXO7 mutations have
been described previously by some of us [10].
Cell culture and transfection
Lymphoblastoid cell lines were obtained by Epstein-Barr virus
(EBV) immortalization of peripheral blood cells obtained from
patients and controls, according to standard protocols. The
lymphoblastoid cells were cultured in RPMI 1640 medium
(Gibco) supplemented with 15% fetal calf serum, 50 U/ml
penicillin and 50 mg/ml streptomycin, in a humidified 5% CO2
incubator. Human Embryonic Kidney (HEK) 293T cells, human
neuroblastoma cells (SH-SY5Y), and human fibroblasts were
grown in Dulbecco’s modified Eagle’s medium (DMEM) (Lonza).
The HEK 293T cells were incubated in a humidified 5% CO2
incubator, and the SH-SY5Y cells and fibroblasts were incubated
in a humidified 10% CO2 incubator. The HEK 293T cells were
transiently transfected by polyethyleneimine (PEI, Polysciences
Inc.). LipofectamineTM LTX and PLUSTM Reagents (Invitrogen)
transfection were used in SH-SY5Y cells according to the
manufacturer’s instructions. Furthermore, stable FBXO7 knock
down HEK 293T cells were generated using FBXO7 shRNA
(#TRCN 0000004339, Sigma); a non-targeting vector (shNT)
(SHC002, Sigma) was used as control. Mouse primary hippocam-
pal neurons were dissected and cultured as described previously
[23]. After 20 days in vitro, the hippocampal neurons were
transfected with constructs expressing wild type or mutant FBXO7
by using Lipofectamine 2000 (Invitrogen).
FBXO7 constructs
The full-length FBXO7 cDNA (GenBank accession number
NM_012179.3; NP_036311.3) was amplified by PCR using cDNA
obtained from SH-SY5Y neuroblastoma cells as template. The
PCR product was ligated into pcDNATM3.1/V5-His-TOPO
(Invitrogen). After sequencing, the insert WT FBXO7 was
subcloned in frame into the mammalian expression plasmid
pEGFP-C3 (BD biosciences), resulting in an N-terminal fusion
protein eGFP-FBXO7. All primers used are given in the
Supplementary Table S1. The untagged WT FBXO7 was obtained
using the QuikChange site-directed mutagenesis kit (Stratagene)
by introducing a stop codon in front of the V5-His tag. All
untagged FBXO7 mutants (T22M, R378G, and R498X) were also
prepared using the above-mentioned mutagenesis kit. The cDNA
fragment encoding the first 40 amino acids of WT or T22M-
mutant FBXO7 isoform 1 was amplified and subcloned in front of
mCherry-labeled profilin (the mCherry-profilin construct was a
gift from Josien Levenga, Clinical Genetics Department, Erasmus
MC). The complete cDNA open reading frame of all constructs
was verified by direct sequencing.
Immunofluorescence
The HEK 293T and SH-SY5Y cells were seeded onto glass
coverslips coated with 0.1% gelatin (Sigma-Aldrich), and trans-
fected with untagged WT or mutant FBXO7 constructs. The cells
were fixed in 4% (w/v) paraformaldehyde in PBS for 10 minutes
and permeabilized in 100% methanol for 20 minutes. The cells
were then blocked with 3% bovine serum albumin (BSA, Sigma) in
PBS (w/v) for 30 minutes, and probed at 4uC overnight with
mouse polyclonal antibody raised against full-length FBXO7
(Abnova, 1/300). The samples were then incubated with Cy3-
coupled secondary anti-mouse antibodies (Jackson ImmunoRe-
search, 1/200) for 1 hour. The cell nuclei were stained with
Hoechst dye 33342 (Invitrogen), but the staining is shown in green
color to increase image contrast. Cells were then mounted on
slides with fluorescent mounting medium (DAKO). Fluorescence
images were collected using a Leica SP5 confocal microscope
(Leica Microsystems), and analyzed with the Leica Confocal
Software.
Immunofluorescence of primary hippocampal neurons was
performed 24 hours after transfection. The cells were fixed with
4% paraformaldehyde and permeabilized with staining buffer
containing 50 mM Tris, 0.9% NaCl, 0.25% gelatin, and 0.5%
Triton X-100, at pH 7.4. The subsequent antibody incubation
was performed as described above.
Quantitative PCR (qPCR)
Total RNA was isolated by RNA Bee (TEL-TEST Inc.) from
EBV-transformed lymphoblastoid cells and converted into first-
strand cDNA using the iScriptTM cDNA Synthesis Kit (Bio-Rad).
qPCR was carried out using a KAPA SYBRH FAST qPCR Kit
(Kapa Biosystems) in the ABI Prism 7300 Sequence Detection
System (Applied Biosystems). Thermal cycling conditions in the
ABI Prism 7300 Detection System were as follows: denaturing step
(95uC for 3 minutes), followed by 35 cycles of denaturing (95uC for
5 seconds), annealing and extension (60uC for 30 seconds).
Fluorescence detection and data analysis were performed by
ABI Prism 7300 SDS software (version 1.3.1, Applied Biosystems).
Experiments were performed in triplicate using hypoxanthine
phosphoribosyltransferase (HPRT) as the endogenous control for
gene expression normalization.
The primers used for the qPCR studies, including one assay for
the total FBXO7 transcripts (isoform 1 and isoform 2), one assay
specific for the isoform 1, and another assay specific for the
isoform 2, are given in Supplementary Table S2.
Western Blotting
The cells were washed with cold phosphate buffer (PBS) and
harvested in lysis buffer containing 20mM Tris-HCl at pH 8.0,
150mM NaCl, 1mM NaVO4, 50mM NaF, 1% Triton X-100, and
a protease inhibitor cocktail (Roche Molecular Biochemicals). The
cells were lysed for 30 minutes on ice before centrifugation
(15000 g for 10 minutes at 4uC), and then the total protein
concentration of the supernatant was determined by using the
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bicinchoninic acid (BCATM) protein assay kit (Pierce) according to
the manufacturer’s instructions. The protein samples (40 micro-
grams) were separated by 6%–12% CriterionTM XT 4–12% Bis-
Tris Gel (Bio-Rad), and then transferred to nitrocellulose
membranes. Membranes were blocked with 5% low-fat milk
powder (Fluka) in 16PBS containing 0.1% Tween20 (PBST) for
1 hour at room temperature and incubated overnight at 4uC with
mouse polyclonal antibody against full length FBXO7 (Abnova, 1/
3000) and mouse monoclonal against actin (Abcam, 1/2500) or
against eGFP (Roche, 1/2000). After washing 3 times with PBST,
the membranes were incubated in the dark for 1 hour with PBST
containing donkey anti-mouse secondary antibodies (800nm, LI-
COR Biosciences Lincoln, 1/5000 dilution). After washing, the
membranes were scanned using the Odyssey TM Infrared Imager
(Li-COR Biosciences). The integrated intensities of the protein
bands were quantified by the Odyssey software.
Proteasome and lysosomal-mediated degradation of
FBXO7 mutants
The HEK 293T cells were seeded onto 6-well plates and
transfected with 1.5 mg FBXO7 constructs; empty vector pcDNA3
(Invitrogen, Carlsbad, CA, U.S.A.) was used as mock control. To
test for the proteasomal degradation of the FBXO7 protein,
40 hours after transfection the cultured medium was replaced with
DMEM containing either 42 mM MG-132 (Sigma-Aldrich) or
vehicle control DMSO. After 6 hours incubation, the cells were
harvested and analyzed by WB. The lysosomal degradation
pathway was tested by adding 30mM NH4Cl to the cell culture
28 hours after transfection. The cells were incubated with NH4Cl
for 20 hours and harvested for WB analysis.
FBXO7 protein studies in human brain tissue
Human brain tissues were obtained from The Netherlands
Brain Bank, Netherlands Institute for Neuroscience, Amsterdam.
All material has been collected from donors from whom a written
informed consent for brain autopsy and the use of the material and
clinical information for research purposes had been obtained by
the Netherlands Brain Bank. For immunohistochemistry, paraffin-
embedded sections (7 mm) were analyzed from the brain of two
non-parkinsonian, non-demented male donors (age at death 76
and 81 years-old). The following regions were studied: frontal,
temporal, and occipital cerebral cortex, globus pallidum, hippo-
campus, substantia nigra, and cerebellum. Briefly, dewaxed
sections were pretreated for antigen retrieval using pressure
cooking in 0.1 M sodium citrate buffer (pH 6) for 5 min.
Subsequently, sections were incubated overnight with antibodies
against FBXO7 (Abnova, 1:100) at 4uC. The broad spectrum
poly–AP powervision reagent (immunoLogic) was used for 1 hour
at room temperature for visualization. Enzyme detection was
performed by using 1% new fuchsin, 1% sodiumnitrite, 0.03%
naphtol AS-MX phosphate (Sigma), and 0.025% levamisol (Acros)
for 20 minutes at room temperature. The sections were not
counterstained but directly mounted in aquamount for examina-
tion under a light microscope.
Data analysis and statistics
Quantitative data are expressed as means 6 SEM based on at
least three independent experiments. Statistical analyses were
performed using contingency tables.
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Figure S1 Validation of the specificity of the FBXO7 antibody
by Western blotting in stable FBXO7 gene knock down HEK 293T
cells.
(PDF)
Figure S2 Validation of the specificity of the FBXO7 antibody
by immunofluorescence in stable FBXO7 gene knock down HEK
293T cells.
(PDF)
Figure S3 qPCR analysis of FBXO7 isoform-specific transcripts
in members of the PARK15 families and unrelated healthy
controls (C1–C3).
(PDF)
Figure S4 Overexpression of wild type and mutant FBXO7.
(PDF)
Figure S5 Positively charged amino acids in the FBXO7
protein.
(PDF)
Table S1 Primers used for molecular cloning.
(PDF)
Table S2 Primers used for qPCR.
(PDF)
Acknowledgments
We thank the family members for their participation, Dr. Mark Nellist and
Dr. Andre Hoogeveen (Dept. Clinical Genetics, Erasmus MC, Rotterdam)
for their helpful advices, and Tom de Vries Lentsch for artwork.
Author Contributions
Conceived and designed the experiments: TZ EDG BAO VB. Performed
the experiments: TZ EDG GJB AL LAS. Analyzed the data: TZ EDG GJB
RW VB. Contributed reagents/materials/analysis tools: CHW FWV
MCJD PM. Wrote the paper: TZ VB. Revised the paper for important
intellectual content: EDG BAO.
References
1. Tolosa E, Wenning G, Poewe W (2006) The diagnosis of Parkinson’s disease.
Lancet Neurol 5: 75–86.
2. Gupta A, Dawson VL, Dawson TM (2008) What causes cell death in Parkinson’s
disease? Ann Neurol 64 Suppl 2: S3–15.
3. Gasser T (2009) Molecular pathogenesis of Parkinson disease: insights from
genetic studies. Expert Rev Mol Med 11: e22.
4. Bonifati V (2007) Genetics of parkinsonism. Parkinsonism Relat Disord 13
(Suppl 3): S233–S241.
5. Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, et al. (2008)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated
Parkinson’s disease: a case-control study. Lancet Neurol 7: 583–590.
6. Ahlskog JE (2009) Parkin and PINK1 parkinsonism may represent nigral
mitochondrial cytopathies distinct from Lewy body Parkinson’s disease.
Parkinsonism Relat Disord 15: 721–727.
7. Bonifati V (2010) PARK7, DJ1. In: Kompoliti K, Verhagen Metman L, eds.
Encyclopedia of Movement Disorders. Oxford: Academic Press 3: 392–395.
8. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, et al. (2006)
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2,
encoding a lysosomal type 5 P-type ATPase. Nat Genet 38: 1184–1191.
9. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, et al. (2009)
Alpha-synuclein is part of a diverse and highly conserved interaction network
that includes PARK9 and manganese toxicity. Nat Genet 41: 308–315.
10. Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, et al. (2009)
FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyrami-
dal syndrome. Neurology 72: 240–245.
11. Shojaee S, Sina F, Banihosseini SS, Kazemi MH, Kalhor R, et al. (2008)
Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree
by 500 K SNP arrays. Am J Hum Genet 82: 1375–1384.
12. Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, et al. (1999)
Identification of a family of human F-box proteins. Curr Biol 9: 1177–1179.
13. Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW (1999) A family of
mammalian F-box proteins. Curr Biol 9: 1180–1182.
Nuclear Activity of FBXO7 Is Lost in PARK15
PLoS ONE | www.plosone.org 12 February 2011 | Volume 6 | Issue 2 | e16983
14. Ilyin GP, Rialland M, Pigeon C, Guguen-Guillouzo C (2000) cDNA cloning and
expression analysis of new members of the mammalian F-box protein family.
Genomics 67: 40–47.
15. Ho MS, Ou C, Chan YR, Chien CT, Pi H (2008) The utility F-box for protein
destruction. Cell Mol Life Sci 65: 1977–2000.
16. Kirk R, Laman H, Knowles PP, Murray-Rust J, Lomonosov M, et al. (2008)
Structure of a Conserved Dimerization Domain within the F-box Protein Fbxo7
and the PI31 Proteasome Inhibitor. J Biol Chem 283: 22325–22335.
17. Hsu JM, Lee YC, Yu CT, Huang CY (2004) Fbx7 functions in the SCF complex
regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein
(HURP) proteolysis by a proline-rich region. J Biol Chem 279: 32592–32602.
18. Chang YF, Cheng CM, Chang LK, Jong YJ, Yuo CY (2006) The F-box protein
Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes
cIAP1 ubiquitination. Biochem Biophys Res Commun 342: 1022–1026.
19. Laman H, Funes JM, Ye H, Henderson S, Galinanes-Garcia L, et al. (2005)
Transforming activity of Fbxo7 is mediated specifically through regulation of
cyclin D/cdk6. Embo J 24: 3104–3116.
20. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE (2004) Nonsense-mediated
decay approaches the clinic. Nat Genet 36: 801–808.
21. Boulikas T (1994) Putative nuclear localization signals (NLS) in protein
transcription factors. J Cell Biochem 55: 32–58.
22. French CA, Tambini CE, Thacker J (2003) Identification of functional domains
in the RAD51L2 (RAD51C) protein and its requirement for gene conversion.
J Biol Chem 278: 45445–45450.
23. Levenga J, Buijsen RA, Rife M, Moine H, Nelson DL, et al. (2009)
Ultrastructural analysis of the functional domains in FMRP using primary
hippocampal mouse neurons. Neurobiol Dis 35: 241–250.
Nuclear Activity of FBXO7 Is Lost in PARK15
PLoS ONE | www.plosone.org 13 February 2011 | Volume 6 | Issue 2 | e16983
